Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q2 EPS by 34c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q2 EPS of ($1.07), $0.34 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Dataram (DRAM) call put ratio 1.4 calls to 1 put into SK Hynix plans to raise up to $29B
• Goldman Sachs Upgrades Nitto Boseki Co Ltd (3110:JP) to Buy
• BTIG Reiterates Buy Rating on Duke Energy (DUK) Ahead of North Carolina Rate Cases